Scribe, Jen­nifer Doud­na's newest start­up, nabs a mega-round and a vo­cal in­vestor

Near­ly a decade ago, when the first CRISPR com­pa­nies start­ed look­ing for cap­i­tal, Be­hzad Ag­haz­adeh passed.

Ag­haz­adeh, one of biotech’s more opin­ion­at­ed in­vestors, had in­vest­ed in gene edit­ing be­fore, but he had reser­va­tions about these com­pa­nies: How would they nav­i­gate the patent jun­gle that cropped up around CRISPR-Cas9? How read­i­ly could they ac­tu­al­ly turn this bac­te­r­i­al-de­rived sys­tem in­to a hu­man ther­a­py? He main­tains those con­cerns, even with those com­pa­nies now worth over $1 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER